Assessment of Pharmacovigilance Reporting in Russia

The risk-based approach to pharmacovigilance control implemented in Russia since January 1, 2018 increases the responsibility of manufacturers and developers of medicines. The purpose of the work is to assess the system of Express reporting and Periodic reporting on the safety of drugs in accordance with the relevant requirements of the legislation of the Russian Federation and the Eurasian Economic Union. The article continues a series of publications on recommendations for the preparation of reporting forms on pharmacovigilance. The article presents the results of the assessment of the state of elements of the system of drug safety control in Russia in terms of the preparation of reporting forms in accordance with the current regulatory requirements of national and international legislation for holders of registration certificates of medicines for medical use and developers of medicines. Recommendations for proper preparation of periodic reporting are proposed. The range of problems requiring additional assessment, in particular, the state of the system of regional centers for monitoring the safety of medicines in Russia is highlighted. The article is addressed to clinical pharmacologists, pharmacovigil commissioners, pharmacovigilance specialists, heads of medical and pharmaceutical organizations and medical authors.

1. Snegireva II, Zatolochina KE, Ozeretskovsky NA, Romanov BK, Mironov AN. Vaccine pharmacovigilance in Russia: legal and regulatory framework, current stage of development. Vedomosti Nauchnogo tsentra ekspertizy sredstv meditsinskogo primeneniya = The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. 2014;(4):27–31 (In Russ.)

2. Makoveev AN, Berezina VS. Russian pharmacovigilance — 2016. Razrabotka i registratsiya lekarstvennykh sredstv = Drug Development and Registration. 2015;(2):230–6 (In Russ.)

3. Romanov BK, Alyautdin RN, Darmostukova MA, Glagolev SV, Polivanov VA. Standard form of the Periodic Safety Update Report. Bezopasnost’ i risk farmako terapii = Safety and Risk of Pharmacotherapy. 2017;5(4):148–60 (In Russ.)

4. Gildeeva GN, Yurkov VI. Pharmacovigilance in Russia: Challenges, Prospects and Current State of Affairs. J Pharmacovigil. 2016;(4):206. https://doi.org/10.4172/2329-6887.1000206

5. Kuznetsov YA, Tikhonov SA, Berezina VS. Organization of the pharmacovigilance system in pharmaceutical company. Razrabotka i registratsiya lekarstvennykh sredstv = Drug Development and Registration. 2015;(4):172–80 (In Russ.)

6. Gildeeva GN, Glagolev SV, Yurkov VI. Problems of drug safety monitoring in Russia: role of pharmacovigilance experts. Vestnik Roszdravnadzora = Bulletin of Roszdravnadzor. 2016;(5):114–8 (In Russ.)

7. Murashko MA, Parhomenko DV, Asetskaya IL, Kosenko VV, Polivanov VA, Glagolev SV. The role and practice of pharmacovigilance in russian healthcare. Vestnik Roszdravnadzora = Bulletin of Roszdravnadzor. 2014;(3):54–61 (In Russ.)

8.